AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (96.9%). Net sales break down by treatment area between oncology (34%), cardiovascular, renal and metabolic diseases (21.4%), respiratory and autoimmune diseases (13.4%), and other (31.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (3.1%). Net sales are distributed geographically as follows: the United Kingdom (7%), Europe (20.1%), Americas (44.2%) and Africa/Asia/Australia (28.7%).

Sector

Pharmaceuticals

Calendar

2023-12-05 - Berenberg European Conference

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Moderating our over-optimistic expectations for improved profitability

November 10, 2023 at 12:42 pm EST

'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

February 09, 2023 at 10:04 am EST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

127.81USD

Average target price

165.55USD

Spread / Average Target

+29.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	-9.70%	198 B $
ELI LILLY AND COMPANY	+61.62%	529 B $
NOVO NORDISK A/S	+44.67%	444 B $
JOHNSON & JOHNSON	-11.25%	382 B $
MERCK & CO., INC.	-4.75%	269 B $
ABBVIE INC.	-9.29%	255 B $
NOVARTIS AG	+1.56%	200 B $
PFIZER, INC.	-43.64%	164 B $
AMGEN INC.	+2.94%	145 B $
SANOFI	-4.13%	117 B $

Other Pharmaceuticals

Market Closed - London Stock Exchange Other stock markets 11:35:11 2023-12-06 am EST			5-day change	1st Jan Change
10,130 ^GBX	-0.14%		+0.98%	-9.70%

09:46am	AstraZeneca's Koselugo Now Available in Malaysia for Pneumiatric Patients with Symptomatic Neurofibromatosis Type 1plexiform Neurofibromas	CI
Dec. 05	Altimmune open to partnerships, deals with drugmakers, says CEO	RE

AstraZeneca's Koselugo Now Available in Malaysia for Pneumiatric Patients with Symptomatic Neurofibromatosis Type 1plexiform Neurofibromas	03:46am	CI
Altimmune open to partnerships, deals with drugmakers, says CEO	Dec. 05	RE
Anything is possible	Dec. 05
JPMorgan Trims AstraZeneca PT, Affirms Overweight Rating	Dec. 05	MT
Analyst recommendations: Broadcom, Deere & Co, Rio Tinto, Lululemon, Nike...	Dec. 05
Goldman lifts Landsec and British Land	Dec. 05	AN
Wuxi Bio Selloff Extends as Analysts Cut Forecasts	Dec. 05	DJ
ASTRAZENECA : Gets a Buy rating from JP Morgan	Dec. 05	ZD
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04	RE
GLOBAL MARKETS LIVE : Roche, Uber, Amazon, Spotify, 888...	Dec. 04
AstraZeneca: AI collaboration with Absci	Dec. 04	CF
Model N: A niche positioning	Dec. 04
Absci Shares Rise 27% After Announcing Collaboration With AstraZeneca	Dec. 04	DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday	Dec. 04	MT
Sector Update: Health Care	Dec. 04	MT
Absci Working With AstraZeneca to Use AI Platform to Discover Oncology Candidate	Dec. 04	MT
Absci Corporation Announces Collaboration with Astrazeneca to Advance Ai-Driven Oncology Candidate	Dec. 04	CI
UK Stocks-Factors to watch on Dec 4	Dec. 04	RE
Roche enters obesity drug market with $2.7 bln Carmot deal	Dec. 04	RE
AstraZeneca, Absci Enter $247 Million Partnership to Develop New Cancer Treatment	Dec. 03	MT
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT	Dec. 03	RE
AstraZeneca ties up with AI biologics company to develop cancer drug - FT	Dec. 03	RE
US obesity docs expect Lilly weight-loss drug to show similar heart benefit as Wegovy	Dec. 01	RE
Global markets live: Meta, Tesla, BP Plc, Pfizer, General Motors...	Dec. 01
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Dec. 01	MT